Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck
Stopped The study did not continue to phase II due to the importance of HPV status as a prognostic factor to guide treatment decisions.
Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Basaloid Squamous Cell Carcinoma
- Undifferentiated Carcinoma
- Adenosquamous Cell Carcinoma
Interventions
- DRUG: Abraxane
- DRUG: Erbitux
- DRUG: Carboplatin
- RADIATION: Intensity Modulated Radiation Therapy
Sponsor
Dana-Farber Cancer Institute
Collaborators